INTELLIA THERAPEUTICS INC (NTLA) Fundamental Analysis & Valuation

NASDAQ:NTLA • US45826J1051

Current stock price

13.26 USD
+0.45 (+3.51%)
At close:
13.25 USD
-0.01 (-0.08%)
After Hours:

This NTLA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. NTLA Profitability Analysis

1.1 Basic Checks

  • In the past year NTLA has reported negative net income.
  • NTLA had a negative operating cash flow in the past year.
  • NTLA had negative earnings in each of the past 5 years.
  • NTLA had a negative operating cash flow in each of the past 5 years.
NTLA Yearly Net Income VS EBIT VS OCF VS FCFNTLA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100M -200M -300M -400M -500M

1.2 Ratios

  • NTLA has a Return On Assets (-49.01%) which is in line with its industry peers.
  • NTLA has a Return On Equity (-61.47%) which is in line with its industry peers.
Industry RankSector Rank
ROA -49.01%
ROE -61.47%
ROIC N/A
ROA(3y)-43.19%
ROA(5y)-36.29%
ROE(3y)-55.6%
ROE(5y)-46.19%
ROIC(3y)N/A
ROIC(5y)N/A
NTLA Yearly ROA, ROE, ROICNTLA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for NTLA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NTLA Yearly Profit, Operating, Gross MarginsNTLA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -500 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. NTLA Health Analysis

2.1 Basic Checks

  • NTLA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for NTLA has been increased compared to 1 year ago.
  • Compared to 5 years ago, NTLA has more shares outstanding
  • NTLA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NTLA Yearly Shares OutstandingNTLA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
NTLA Yearly Total Debt VS Total AssetsNTLA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

2.2 Solvency

  • NTLA has an Altman-Z score of -0.03. This is a bad value and indicates that NTLA is not financially healthy and even has some risk of bankruptcy.
  • NTLA has a better Altman-Z score (-0.03) than 60.31% of its industry peers.
  • There is no outstanding debt for NTLA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.03
ROIC/WACCN/A
WACC9.26%
NTLA Yearly LT Debt VS Equity VS FCFNTLA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M 1B

2.3 Liquidity

  • NTLA has a Current Ratio of 5.08. This indicates that NTLA is financially healthy and has no problem in meeting its short term obligations.
  • NTLA has a Current ratio (5.08) which is comparable to the rest of the industry.
  • NTLA has a Quick Ratio of 5.08. This indicates that NTLA is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of NTLA (5.08) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.08
Quick Ratio 5.08
NTLA Yearly Current Assets VS Current LiabilitesNTLA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. NTLA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 27.05% over the past year.
  • The Revenue has grown by 16.92% in the past year. This is quite good.
  • The Revenue has been growing slightly by 3.14% on average over the past years.
EPS 1Y (TTM)27.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.65%
Revenue 1Y (TTM)16.92%
Revenue growth 3Y9.09%
Revenue growth 5Y3.14%
Sales Q2Q%78.79%

3.2 Future

  • The Earnings Per Share is expected to grow by 19.55% on average over the next years. This is quite good.
  • The Revenue is expected to grow by 110.00% on average over the next years. This is a very strong growth
EPS Next Y3.12%
EPS Next 2Y10.12%
EPS Next 3Y9.87%
EPS Next 5Y19.55%
Revenue Next Year8.99%
Revenue Next 2Y33.18%
Revenue Next 3Y48.47%
Revenue Next 5Y110%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
NTLA Yearly Revenue VS EstimatesNTLA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B 2B
NTLA Yearly EPS VS EstimatesNTLA Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 -5 -10

More info and screens

Find the best growth stocksShow best growing peers

0

4. NTLA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for NTLA. In the last year negative earnings were reported.
  • Also next year NTLA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NTLA Price Earnings VS Forward Price EarningsNTLA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NTLA Per share dataNTLA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.12%
EPS Next 3Y9.87%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NTLA Dividend Analysis

5.1 Amount

  • NTLA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NTLA Fundamentals: All Metrics, Ratios and Statistics

INTELLIA THERAPEUTICS INC

NASDAQ:NTLA (3/25/2026, 8:00:02 PM)

After market: 13.25 -0.01 (-0.08%)

13.26

+0.45 (+3.51%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)05-06
Inst Owners85.56%
Inst Owner Change2.57%
Ins Owners1.34%
Ins Owner Change2.13%
Market Cap1.57B
Revenue(TTM)67.67M
Net Income(TTM)-412.69M
Analysts72
Price Target23.94 (80.54%)
Short Float %39.45%
Short Ratio8.62
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.38%
Min EPS beat(2)9.97%
Max EPS beat(2)14.78%
EPS beat(4)4
Avg EPS beat(4)11.57%
Min EPS beat(4)5.61%
Max EPS beat(4)15.91%
EPS beat(8)7
Avg EPS beat(8)7.15%
EPS beat(12)10
Avg EPS beat(12)6.86%
EPS beat(16)12
Avg EPS beat(16)-0.25%
Revenue beat(2)1
Avg Revenue beat(2)32.73%
Min Revenue beat(2)-11.02%
Max Revenue beat(2)76.48%
Revenue beat(4)3
Avg Revenue beat(4)29.4%
Min Revenue beat(4)-11.02%
Max Revenue beat(4)76.48%
Revenue beat(8)6
Avg Revenue beat(8)32.68%
Revenue beat(12)8
Avg Revenue beat(12)13.01%
Revenue beat(16)12
Avg Revenue beat(16)16.46%
PT rev (1m)0%
PT rev (3m)8.22%
EPS NQ rev (1m)3.33%
EPS NQ rev (3m)3.33%
EPS NY rev (1m)0.26%
EPS NY rev (3m)-0.26%
Revenue NQ rev (1m)22.26%
Revenue NQ rev (3m)22.26%
Revenue NY rev (1m)17.31%
Revenue NY rev (3m)16.98%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 23.15
P/FCF N/A
P/OCF N/A
P/B 2.33
P/tB 2.33
EV/EBITDA N/A
EPS(TTM)-3.83
EYN/A
EPS(NY)-3.71
Fwd EYN/A
FCF(TTM)-3.35
FCFYN/A
OCF(TTM)-3.34
OCFYN/A
SpS0.57
BVpS5.68
TBVpS5.68
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -49.01%
ROE -61.47%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-43.19%
ROA(5y)-36.29%
ROE(3y)-55.6%
ROE(5y)-46.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 11.56%
Cap/Sales 1.67%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.08
Quick Ratio 5.08
Altman-Z -0.03
F-Score4
WACC9.26%
ROIC/WACCN/A
Cap/Depr(3y)74.51%
Cap/Depr(5y)117.57%
Cap/Sales(3y)16.73%
Cap/Sales(5y)22.97%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)27.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%34.65%
EPS Next Y3.12%
EPS Next 2Y10.12%
EPS Next 3Y9.87%
EPS Next 5Y19.55%
Revenue 1Y (TTM)16.92%
Revenue growth 3Y9.09%
Revenue growth 5Y3.14%
Sales Q2Q%78.79%
Revenue Next Year8.99%
Revenue Next 2Y33.18%
Revenue Next 3Y48.47%
Revenue Next 5Y110%
EBIT growth 1Y17.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year3.24%
EBIT Next 3Y3.48%
EBIT Next 5Y16.49%
FCF growth 1Y-11.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-13.14%
OCF growth 3YN/A
OCF growth 5YN/A

INTELLIA THERAPEUTICS INC / NTLA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of INTELLIA THERAPEUTICS INC (NTLA) stock?

ChartMill assigns a fundamental rating of 3 / 10 to NTLA.


Can you provide the valuation status for INTELLIA THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to INTELLIA THERAPEUTICS INC (NTLA). This can be considered as Overvalued.


Can you provide the profitability details for INTELLIA THERAPEUTICS INC?

INTELLIA THERAPEUTICS INC (NTLA) has a profitability rating of 1 / 10.